A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on February 27, 2025, at 12 p.m ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Intellia Therapeutics, Inc. (NTLA) reports results for the quarter ended December 2024. While this widely-known ...

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 ...

Intellia Therapeutics Inc. overhyped its lung-disease therapy study despite inefficiencies and costliness of such viral-editing treatments, sending share prices down 15%, a proposed class action says.

Intellia Therapeutics, Inc. (NTLA) shares rallied 6.5% in the last trading session to close at $12.28. This move can be attributable to notable volume with a higher number of shares being traded ...

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing ...

Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend ...